Genetic Technologies was an early pioneer in recognizing important new applications for "non-coding" DNA (DeoxyriboNucleic Acid). The Company has since been granted patents in 24 countries around the world, securing intellectual property rights for particular uses of non-coding DNA in genetic analysis and gene mapping across all genes in all multicellular species. Its three-pronged business strategy includes: 1) the global commercialization of its patents through an active licensing program; 2) the expansion of its dominant commercial genetic testing business in Australia; and, 3) the commercialization of its various research and development projects aimed at generating further intellectual property of global commercial significance.
Genetic Technologies Limited
ASX:GTG ISIN:AU000000GTG7
新聞
根據澳洲統計局的數據,澳洲建築審批數在11月增長到13,724 幢,經季節因素調整後,較10月份向上修正後的數字12,962幢增加了5.9%。儘管有澳儲行升息和逐步撤消政府首次購房者補貼的舉措,此結果仍好於市場預期。
###
48,594 公司背景瀏覽
- 本頁瀏覽人次: (過去7日: 16) (過去30日: 74) (自發布以來: 8086)